Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2026Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Umbilical cord-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

YNYanyan NiuBCBin ChenYZYaqian Zhao

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved remission rates in SR-aGVHD with UC-MSC treatment, suggesting effectiveness.

Key Points

  • To evaluate the effectiveness of umbilical cord-derived mesenchymal stem cells (UC-MSCs) for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD).
  • Retrospective analysis of 95 patients receiving allo-HSCT from 2019-2024.
  • Comparison of UC-MSCs plus standard care (n=44) vs. standard care alone (n=51).
  • Infusion of UC-MSCs at a dose of 1-3 × 10^6 cells/kg with three infusions per patient.
  • Assessment of complete response (CR) rates at week 4 and identification of prognostic factors.
  • Higher CR rates in MSC group: 84.1% vs. 58.8% for grade II-IV SR-aGVHD (p=0.007).
  • CR rates improved for grade III-IV SR-aGVHD: 54.5% vs. 31.4% (p=0.034).
  • Liver and gut CR rates improved by 31.8% and 28.1%, respectively.
  • Age ≥35 years, grade IV aGVHD, and hemoglobin ≤90 g/L identified as adverse prognostic factors.
  • No significant difference in overall survival after 27 months follow-up (HR=1.04, p=0.911).

Cite This Study

Niu et al. (2026) studied this question.

synapsesocial.com/papers/69cf5dd55a333a821460bd48https://doi.org/10.1080/10428194.2026.2634172
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial2025
  2. 2Mesenchymal stromal cells as add-on therapy to anti-CD25 antibodies for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: a multicenter, single-arm, pivotal clinical trial2026 · 2 citations
  3. 3Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial2024 · 27 citations
  4. 4Gradual treatment effect from mesenchymal stem cell on steroid-refractory aGVHD in patients receiving above 8 infusions and with gut involvement: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial2024 · 1 citations
  5. 5Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up2024 · 1 citations